Free Trial
NYSE:DGX

Quest Diagnostics (DGX) Stock Price, News & Analysis

Quest Diagnostics logo
$187.43 -3.41 (-1.79%)
Closing price 05/8/2026 03:59 PM Eastern
Extended Trading
$187.55 +0.12 (+0.06%)
As of 05/8/2026 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Quest Diagnostics Stock (NYSE:DGX)

Advanced

Key Stats

Today's Range
$186.23
$192.20
50-Day Range
$189.04
$211.75
52-Week Range
$164.65
$213.50
Volume
761,460 shs
Average Volume
1.08 million shs
Market Capitalization
$20.75 billion
P/E Ratio
20.71
Dividend Yield
1.84%
Price Target
$216.58
Consensus Rating
Moderate Buy

Company Overview

Quest Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

DGX MarketRank™: 

Quest Diagnostics scored higher than 95% of companies evaluated by MarketBeat, and ranked 14th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Quest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 7 hold ratings, and no sell ratings.

  • Upside Potential

    Quest Diagnostics has a consensus price target of $216.58, representing about 15.6% upside from its current price of $187.43.

  • Amount of Analyst Coverage

    Quest Diagnostics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Quest Diagnostics' stock forecast and price target.
  • Earnings Growth

    Earnings for Quest Diagnostics are expected to grow by 7.64% in the coming year, from $10.73 to $11.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Quest Diagnostics is 20.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Quest Diagnostics is 20.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.64.

  • Price to Earnings Growth Ratio

    Quest Diagnostics has a PEG Ratio of 2.27. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Quest Diagnostics has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Quest Diagnostics' valuation and earnings.
  • Percentage of Shares Shorted

    3.49% of the float of Quest Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Quest Diagnostics has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Quest Diagnostics has recently decreased by 14.93%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Quest Diagnostics pays a meaningful dividend of 1.80%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Quest Diagnostics has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of Quest Diagnostics is 38.01%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 29.78% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.

  • Read more about Quest Diagnostics' dividend.
  • News Sentiment

    Quest Diagnostics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Quest Diagnostics this week, compared to 7 articles on an average week.
  • Search Interest

    16 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,945,262.00 in company stock.

  • Percentage Held by Insiders

    0.88% of the stock of Quest Diagnostics is held by insiders.

  • Percentage Held by Institutions

    88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Quest Diagnostics' insider trading history.
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DGX Stock News Headlines

DGX Stock Price Prediction
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.tc pixel
Quest Diagnostics: Updating Levels After Q1 Earnings
Quest Diagnostics Incorporated
See More Headlines

DGX Stock Analysis - Frequently Asked Questions

Quest Diagnostics' stock was trading at $173.47 at the beginning of 2026. Since then, DGX stock has increased by 8.0% and is now trading at $187.4320.

Quest Diagnostics Incorporated (NYSE:DGX) released its earnings results on Tuesday, April, 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.13. The company's revenue for the quarter was up 9.2% on a year-over-year basis.
Read the conference call transcript
.

Quest Diagnostics' board authorized a stock buyback plan on Tuesday, February 10th 2026, which authorizes the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 4.7% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

Quest Diagnostics subsidiaries include MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and more.

Quest Diagnostics (DGX) raised $12 million in an IPO on Tuesday, January 7th 2025. The company issued 2,300,000 shares at a price of $4.00-$6.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO.

Top institutional shareholders of Quest Diagnostics include Dimensional Fund Advisors LP (1.76%), Bank of New York Mellon Corp (0.59%), Principal Financial Group Inc. (0.48%) and Swiss National Bank (0.29%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney.
View institutional ownership trends
.

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

Record date for 4/20 Dividend
4/06/2026
Ex-Dividend for 4/20 Dividend
4/06/2026
Dividend Payable
4/20/2026
Last Earnings
4/21/2026
Today
5/08/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - OUTP/HM CRE
Sub-Industry
Health Care Services
Current Symbol
NYSE:DGX
CIK
1022079
Employees
57,000
Year Founded
1967

Price Target and Rating

High Price Target
$235.00
Low Price Target
$178.00
Potential Upside/Downside
+15.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
$9.05
Trailing P/E Ratio
20.71
Forward P/E Ratio
17.47
P/E Growth
2.27
Net Income
$992 million
Net Margins
9.07%
Pretax Margin
12.20%
Return on Equity
15.60%
Return on Assets
7.06%

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
1.18
Quick Ratio
1.08

Sales & Book Value

Annual Sales
$11.04 billion
Price / Sales
1.88
Cash Flow
$14.90 per share
Price / Cash Flow
12.58
Book Value
$69.25 per share
Price / Book
2.71

Miscellaneous

Outstanding Shares
110,700,000
Free Float
109,722,000
Market Cap
$20.75 billion
Optionable
Optionable
Beta
0.60

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NYSE:DGX) was last updated on 5/9/2026 by MarketBeat.com Staff.
From Our Partners